Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Phase II Trial
100%
Bevacizumab
100%
Recurrent Malignant Glioma
100%
Enzastaurin
100%
Glioblastoma
75%
Glioma Patients
75%
Anaplastic Glioma
75%
Peripheral Blood Mononuclear Cells
50%
Three-level
50%
Stable Disease
50%
Glycogen Synthase kinase-3β (GSK-3β)
50%
Enzyme-inducing
50%
Treatment Response
25%
Hypophosphatemia
25%
Clinical Evaluation
25%
Progression-free Survival
25%
Median Overall Survival
25%
Cardiac Magnetic Resonance Imaging (cMRI)
25%
Thrombotic Events
25%
Complete Response
25%
Partial Response
25%
Health-related Quality of Life
25%
Early Response
25%
Intractable Seizures
25%
Objective Response
25%
Antiepileptic Drugs
25%
Serologic
25%
Lymphopenia
25%
Response-adapted
25%
Loading Dose
25%
Long Progression-free Survival
25%
Bevacizumab Therapy
25%
Non-enzyme
25%
Well Tolerated
25%
Median Progression-free Survival
25%
Pharmacology, Toxicology and Pharmaceutical Science
Glioblastoma
100%
Phase II Trials
100%
Bevacizumab
100%
Enzastaurin
100%
Progression Free Survival
37%
Glioma
37%
Enzymes
25%
Glycogen Synthase Kinase 3
25%
Diseases
25%
Hypophosphatemia
12%
Clinical Trial
12%
Monotherapy
12%
Overall Survival
12%
Intractable Epilepsy
12%
Lymphocytopenia
12%
Biochemistry, Genetics and Molecular Biology
Bevacizumab
100%
Phase II Trials
100%
Progression Free Survival
60%
Glycogen Synthase Kinase 3
40%
Enzyme
40%
Peripheral Blood Mononuclear Cell
40%
Magnetic Resonance Imaging
40%
Clinical Trial
20%
Overall Survival
20%
Hypophosphatemia
20%
Loading Drug Dose
20%
Immunology and Microbiology
Bevacizumab
100%
Progression Free Survival
60%
Magnetic Resonance Imaging
40%
Peripheral Blood Mononuclear Cell
40%
Phosphotransferase
40%
Kinase
40%
Glycogen
40%
Overall Survival
20%
Lymphocytopenia
20%
Loading Drug Dose
20%
Neuroscience
Bevacizumab
100%
Glioma
100%
Peripheral Blood Mononuclear Cell
33%
Magnetic Resonance Imaging
33%
Glycogen Synthase Kinase 3
33%
Enzymes
33%
Lymphocytopenia
16%
Anticonvulsant
16%
Quality of Life
16%